This article has Open Peer Review reports available.
Henoch Schönlein purpura associated with pulmonary adenocarcinoma
© Mifune et al; licensee BioMed Central Ltd. 2011
Received: 13 September 2010
Accepted: 22 June 2011
Published: 22 June 2011
Henoch-Schönlein purpura is a common immunoglobulin A-mediated vasculitis syndrome in children. Henoch-Schönlein purpura can also affect adults and is probably related to malignancy.
We report the case of a 61-year-old Japanese man who presented for examination after an abnormal shadow was detected by chest radiography. He received a diagnosis of pulmonary adenocarcinoma, stage IV. Purpura on the legs, abdominal pain, diarrhea, hematuria and proteinuria developed at this time. Henoch-Schönlein purpura was diagnosed, base on the clinical symptoms and histological findings of biopsy specimens of the skin, which showed vasculitis with immunoglobulin A deposits. Our patient received chemotherapy with gemcitabine after successful steroid therapy for the Henoch-Schönlein purpura.
Although hematological malignancies are well-known causes of vasculitides, cases of Henoch-Schönlein purpura associated with lung adenocarcinoma are rare. Our patient was treated with corticosteroid therapy, which cleared the purpura and cytotoxic chemotherapy for the non-small cell lung cancer. However, he died from heart failure due to cardiac tamponade.
Henoch-Schönlein Purpura (HSP) is a systemic vasculitis that involves the small vessels, most notably those in the skin, gastrointestinal tract and glomeruli, and is accompanied by arthralgia or arthritis . HSP occurs commonly in children but can also affect adults . Although the exact cause of HSP remains unknown, malignancy has been reported as a causative factor [3–5]. This report illustrates a rare case of HSP associated with pulmonary adenocarcinoma.
Our patient was diagnosed with HSP. Treatment with prednisolone 0.8 mg/kg/day was initiated following deterioration of renal function, as evidenced by a drop in creatinine clearance from 82 mL/min at the time of admission to 27 mL/min before starting prednisolone. The clinical features of HSP, including abdominal pain and skin rash, resolved within a week. Creatinine clearance improved to 46 mL/min four weeks after the start of steroid treatment. Prednisolone was tapered and maintained at 0.6 mg/kg/day. Our patient received two cycles of chemotherapy with gemcitabine 1000 mg/m2 administered on days one and eight of each three-weeks cycle. HSP was well controlled, and no other adverse events were observed during chemotherapy. Two months after of the start of chemotherapy, the patient developed rapidly progressing dyspnea and hypoxia. Chest CT and cardiac ultrasonography identified tumor invasion of the pericardium and massive pericardial effusion. Cytological examination of the pericardial effusion revealed adenocarcinoma cells. Our patient was diagnosed with heart failure due to cardiac tamponade, and twice underwent surgical drainage of the pericardial effusion. His general condition gradually deteriorated with disease progression, and he died three months after the onset of HSP.
HSP is a systemic vasculitis with IgA-dominant immune deposits affecting small vessels, especially those in the skin, gastrointestinal tract and kidney, and is accompanied by arthralgia or arthritis . HSP occurs more commonly in children. The clinical presentation of HSP is more severe in adults than in children, and the outcome in adults is relatively poor .
The diagnostic criteria for HSP by the American College of Rheumatology are: palpable purpura, patient aged ≤20 years; bowel angina, and granulocytes in the walls of small arterioles or venules seen on biopsy. The presence of two or more of these criteria has a sensitivity and specificity of 87.1% and 87.7%, respectively . Our case met three of the four criteria, with the exception of age. Other vasculitides were highly unlikely because markers for other systemic vasculitides (antistreptolysin O, RF, ANA, ANCA, cryoglobulin, rapid plasma regain, HBsAg, HCV) were all negative. Moreover, immunofluorescent studies of the biopsied skin specimen showed IgA deposition in blood vessels. These findings confirmed HSP. Novák et al. reported that vasculitic endoscopic lesions had been documented in only some patients with HSP with abdominal symptoms . Their findings may explain the finding in our patient's intestinal specimen of non-specific chronic inflammation without vasculitis.
The occurrence of vasculitis in patients with malignancy has been estimated at one in 1800 for hematological malignancies and one in 80,800 for solid tumors . HSP represents only 5% of vasculitis cases associated with malignancy . Although hematological malignancies were more common than solid tumors in all types of vasculitis, solid tumors were more common in association with HSP . Mitsui et al. reported that 23 of 53 patients with HSP (43.4%) aged >40 years had underlying malignancies . The etiology of HSP remains obscure, and various triggers, including bacterial or viral infections, foods and drugs, have been hypothesized. Adult patients with HSP should be investigated for malignancies, especially in the absence of these triggers .
Patients with Henoch-Schönlein purpura and lung cancer.
Occurrence of vasculitis in relation to tumor
eight months before tumor
22 months before tumor
Prednisone + azathioprine
six months before tumor
six months before tumor
Methylprednisolone pulses, prednisone
Blanco R 
Ponge T 
eight months before tumor
five months before tumor
Prednisone + intravenous gammaglobulins
Treatment for patients with HSP and lung cancer is also summarized in Table 1. Therapies for lung cancer induced remission of HSP in some cases [9, 10, 15, 16], whereas other case reports indicated that corticosteroid therapy was required for improvement of HSP [11, 14, 17, 18], as with our case. Our patient had an Eastern Cooperative Oncology Group performance status of 1, and after treatment of the HSP to correct the progressive renal insufficiency, there was no contraindication for chemotherapy. Corticosteroid therapy obviously contributed to the improvement of the HSP and safe chemotherapy. Unfortunately, the patient did not respond to chemotherapy and died from causes associated with the underlying cancer. Mitsui et al. found a correlation between the development of HSP and poor prognosis of malignancies . They reported that seven of nine patients with HSP and malignancies exhibited new metastatic lesions or died of cancer within one-32 months from the onset of HSP.
We report a rare case of HSP associated with non-small cell lung cancer. To the best of our knowledge, this is only the third case of HSP presenting with pulmonary adenocarcinoma. Although the optimum treatment of HSP with malignancy remains unclear, corticosteroid therapy dramatically improved our patient's clinical symptoms, and contributed to the management of his lung cancer.
Written informed consent was obtained from the patient's spouse for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CG: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994, 37: 187-192.2. 10.1002/art.1780370206.View ArticlePubMedGoogle Scholar
- Pillebout E, Thervet E, Hill G, Alberti C, Vanhille P, Nochy D: Henoch-Schönlein purpura in adults: outcome and prognostic factors. J Am Soc Nephrol. 2002, 13: 1271-1278. 10.1097/01.ASN.0000013883.99976.22.View ArticlePubMedGoogle Scholar
- Greer JM, Longley S, Edwards NL, Elfenbein GJ, Panush RS: Vasculitis associated with malignancy. Experience with 13 patients and literature review. Medicine (Baltimore). 1988, 67: 220-230.View ArticleGoogle Scholar
- Fain O, Hamidou M, Cacoub P, Godeau B, Wechsler B, Pariès J, Stirnemann J, Morin AS, Gatfosse M, Hanslik T: Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007, 57: 1473-1480. 10.1002/art.23085.View ArticlePubMedGoogle Scholar
- Zurada JM, Ward KM, Grossman ME: Henoch-Schönlein purpura associated with malignancy in adults. J Am Acad Dermatol. 2006, 55: S65-70. 10.1016/j.jaad.2005.10.011.View ArticlePubMedGoogle Scholar
- Mills JA, Michel BA, Bloch DA, Calabrese LH, Hunder GG, Arend WP, Edworthy SM, Fauci AS, Leavitt RY, Lie JT: The American College of Rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura. Arthritis Rheum. 1990, 33: 1114-1121.View ArticlePubMedGoogle Scholar
- Novák J, Márki-Zay J, Csiki Z, Sebesi J, Takáts A, Sipka S: Schoenlein-Henoch purpura in adulthood (gastrointestinal manifestation and endoscopy). Z Gastroenterol. 2001, 39: 775-782. 10.1055/s-2001-17195.View ArticlePubMedGoogle Scholar
- Mitsui H, Shibagaki N, Kawamura T, Matsue H, Shimada S: A clinical study of Henoch-Schönlein Purpura associated with malignancy. J Eur Acad Dermatol Venereol. 2009, 23: 394-401. 10.1111/j.1468-3083.2008.03065.x.View ArticlePubMedGoogle Scholar
- Cairns SA, Mallick NP, Lawler W, Williams G: Squamous cell carcinoma of bronchus presenting with Henoch-Schönlein purpura. Br Med J. 1978, 2: 474-475.View ArticlePubMedPubMed CentralGoogle Scholar
- Maurice TR: Carcinoma of bronchus presenting with Henoch- Schönlein purpura. Br Med J. 1978, 2: 831-View ArticleGoogle Scholar
- Mitchell DM, Hoffbrand BI: Relapse of Henoch- Schönlein disease associated with lung carcinoma. J R Soc Med. 1979, 72: 614-615.PubMedPubMed CentralGoogle Scholar
- Pfitzenmeyer P, Besancenot JF, Brichon P, González G, André F: The association of bronchial carcinoma and rheumatoid purpura(French). Ann Med Interne (Paris). 1989, 140: 423-424.Google Scholar
- Gutiérrez Maciás A, Alonso Alonso J, Sanz C, Aguirre Errasti C: Schoenlein-Henoch purpura and epidermoid carcinoma of the lung (Spanish). Rev Clin Esp. 1992, 191: 282-283.PubMedGoogle Scholar
- Frigui M, Kechaou M, Ben Hmida M, Kamoun K, Khanfir A, Frikha M, Hachicha J, Bahloul Z: Adult Schönlein-Henoch purpura associated with epidermoid carcinoma of the lung (French). Nephrol Ther. 2009, 5: 201-204.View ArticlePubMedGoogle Scholar
- Blanco R, González-Gay MA, Ibáñez D, Alba C, Pérez de Llano LA: Henoch- Schönlein purpura as a clinical presentation of small cell lung cancer. Clin Exp Rheumatol. 1997, 15: 545-547.PubMedGoogle Scholar
- Ponge T, Boutoille D, Moreau A, Germaud P, Dabouis G, Baranger T, Barrier J: Systemic vasculitis in a patient with small-cell neuroendocrine bronchial cancer. Eur Respir J. 1998, 12: 1228-1229. 10.1183/09031936.98.12051228.View ArticlePubMedGoogle Scholar
- Weiler-Bisig D, Ettlin G, Brink T, Arnold W, Glatz-Krieger K, Fischer A: Henoch- schonlein purpura associated with esophagus carcinoma and adenocarcinoma of the lung. Clin Nephrol. 2005, 63: 302-304.View ArticlePubMedGoogle Scholar
- Solans-Laqué R, Bosch-Gil JA, Pérez-Bocanegra C, Selva-O'Callaghan A, Simeón-Aznar CP, Vilardell-Tarres M: Paraneoplastic vasculitis in patients with solid tumors: report of 15 cases. J Rheumatol. 2008, 35: 294-304.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.